[1]宋晓龙,魏 龙,秦晋铝,等.甲状腺乳头状癌患者术前血清TK1 表达水平联合甲状腺超声特征构建中央区淋巴结转移预测模型及验证[J].现代检验医学杂志,2023,38(01):1-5+72.[doi:10.3969/j.issn.1671-7414.2023.01.001]
　SONG Xiao-long,WEI Long,QIN Jin-lü,et al.Construction and Validation of Prediction Model of Central Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma Based on Preoperative Serum TK1 Expression Level and Thyroid Ultrasound Features[J].Journal of Modern Laboratory Medicine,2023,38(01):1-5+72.[doi:10.3969/j.issn.1671-7414.2023.01.001]
点击复制

甲状腺乳头状癌患者术前血清TK1 表达水平联合甲状腺超声特征构建中央区淋巴结转移预测模型及验证()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年01期
页码:
1-5+72
栏目:
论著
出版日期:
2023-01-15

文章信息/Info

Title:
Construction and Validation of Prediction Model of Central Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma Based on Preoperative Serum TK1 Expression Level and Thyroid Ultrasound Features
文章编号:
1671-7414（2023）01-001-06
作者:
宋晓龙; 魏 龙; 秦晋铝; 杨 茹; 周建平
（陕西省人民医院放免中心，西安 710068）
Author(s):
SONG Xiao-long;  WEI Long;  QIN Jin-lü;  YANG Ru; ZHOU Jian-ping
(Radiation and Immunization Center, Shaanxi Provincial People’s Hospital, Xi’an 710068, China)
关键词:
甲状腺乳头状癌; 血清胸苷激酶; 中央区淋巴结; 预测模型
分类号:
R736.1；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.01.001
文献标志码:
A
摘要:
目的 探讨血清胸苷激酶1(serum thymidine kinase 1,sTK1) 联合甲状腺超声特征预测甲状腺乳头状癌（papillarythyroid carcinoma，PTC）患者中央区淋巴结转移（central lymph node metastasis, CLNM）的风险。方法 选取2020 年10 月~2021 年12 月陕西省人民医院确诊的CLNM 的PTC 患者110 例为观察组，同期无CLNM 的PTC 患者104 例为对照组。所有患者行甲状腺超声检查，检测sTK1 等指标水平，采用t 检验比较两组间sTK1 等指标的水平差异，卡方检验分析颈部超声结果的差异，Logistic 回归分析CLNM 的独立危险因素，构建列线图预测模型，并选取2022 年1~5 月陕西省人民医院确诊的80 例PTC 患者对模型的预测准确度进行外部验证。结果 观察组sTK1 水平高于对照组（2.06±0.75pmol/L vs 1.59±0.66pmol/L），差异有统计学意义（t = 4.75，P < 0.001），而血清TSH，TG，TGAb 水平与是否发生CLNM 无关，差异无统计学意义（t=0.74，0.75，0.61，均P > 0.05）。sTK1 预测PTC 患者CLNM 的曲线下面积（AUC）为0.678，截断值为1.50 pmol/L，灵敏度和特异度分别为79.1%，61.0%。单因素分析结果显示，sTK1> 1.5pmol/L，边界不清、结节微钙化、肿瘤数目、肿瘤直径>1cm 和淋巴结明显血流信号是PTC 患者CLNM 的独立风险因素（χ2=5.24~26.72，均P < 0.05），而性别、年龄、低回声、纵横比>1、肿瘤位置与CLNM 无关（χ2=0.27~7.16，均P> 0.05）。基于上述危险因素构建预测模型并进行准确度验证，采用建模原始数据进行内部验证AUC 为0.826，验证队列进行外部验证AUC 为0.809，表明该模型具有一定的预测准确度。结论 PTC 患者术前sTK1 表达水平联合甲状腺超声特征构建CLNM 预测模型具有一定的临床应用价值，当sTK1> 1.5 pmol/L，边界不清、结节微钙化、肿瘤多灶、肿瘤直径>1cm，淋巴结有明显血流信号时，发生CLNM 的概率较高，建议行预防性中央区淋巴结清扫术。
Abstract:
Objective To explore the prediction of the risk of central lymph node metastasis (CLNM) in patients with papillary thyroid carcinoma (PTC) by serum thymidine kinas 1 (sTK1) combined with thyroid ultrasound features. Methods From October 2020 to December 2021, 110 PTC patients with CLNM diagnosed by Shaanxi Provincial People’s Hospital were selected as the observation group, and 104 PTC patients without lymph node metastasis in the central region were selected as the control group. All patients were examined by thyroid ultrasound and the level of sTK1 and other indicators were detected. The difference of 104 PTC patients without lymph node metastasis in the ceatral region were selected as the control group, and other indicators between the two groups was compared by t-test, the difference of neck ultrasound results was analyzed by Chi square test (χ2 test), and the independent risk factors of CLNM were analyzed by logistic regression. A nomogram prediction model was constructed. 80 PTC patients diagnosed by Shaanxi Provincial People’s Hospital from January 2022 to May 2022 were selected for external verification of the prediction accuracy of the model. Results The level of sTK1 in the observation group was higher than that in the control group（2.06±0.75pmol/L vs 1.59±0.66pmol/L）, and the difference was statistically significant (t=4.75, P<0.001). The levels of serum TSH, TG and TGAb were not related to CLNM, and the differences were no statistically significant (t=0.74, 0.75, 0.61, all P>0.05). The area under the curve (AUC) predicted by sTK1 for CLNM in PTC patients was 0.678,the cut-off value was 1.50 pmol/L, and the sensitivity and the specificity was 79.1%, 61.0%, respectively. The results of univariate analysis showed that sTK1> 1.5 pmol/L, unclear boundary, nodule microcalcifications, tumor number, tumor diameter>1cm and obvious blood flow signal of lymph nodes were independent risk factors of CLNM in PTC patients (χ2=5.24~26.72, all P<0.05), while gender, age, low echo, aspect ratio>1, and tumor location were not related to CLNM (χ2=0.27~7.16, all P>0.05). Based on the above risk factors, a prediction model was built and its accuracy was verified. The AUC of the internal verification using the modeling raw data was 0.826, and the AUC of the external verification using the verification queue was 0.809, which indicates that the model had a certain prediction accuracy. Conclusion The expression of sTK1 in PTC patients before operation combined with the characteristics of thyroid ultrasound to construcs a prediction modesl of CLNM has certain clinical application value. When sTK1>1.5 pmol/L, irregular edges, microcalcifications, multiple tumors, tumor diameter>1 cm, and lymph nodes had obvious blood flow signals, the probability of CLNM is much higher. It is recommended to perfrom preventive lymph node dissection the central region.

参考文献/References:

[1] BRAY F, FERLAY J,SOERJOMATARAM I, et al.Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.[J]. CA: A Cancer Journal for Clinicians,2018,68(6):394-424.
[2] ZHANG Qiang, WANG Zhengmin, MENG Xianying,et al. Predictors for central lymph node metastases in cN0 papillary thyroid microcarcinoma (mPTC): A retrospective analysis of 1 304 cases [J]. Asian Journal of Surgery, 2019, 42(4):571-576.
[3] 王晓庆, 魏玮, 魏玺, 等. 甲状腺乳头状癌的超声表现及其与颈部中央区淋巴结转移的关系[J]. 中华肿瘤杂志, 2018, 40(3):196-200.
WANG Xiaoqing, WEI Wei, WEI Xi, et al. Study on the relationship between ultrasonographic features of papillary thyroid carcinoma and central cervical lymph node metastasis [J]. Chinese Journal of Oncology,2018, 40(3):196-200.
[4] 王伟斌, 苏星韵, 阮佳莹, 等. 2 682 例甲状腺乳头状癌临床病理及预后分析[J]. 中华普通外科杂 志,2018,33(5):393-397.
WANG Weibin, SU Xingyun, RUAN Jiaying, et al. Transition analysis in the clinicopathology and prognosis of 2 682 papillary thyroid carcinoma cases over a 15-year period [J]. Chinese Journal of General Surgery, 2018, 33(5): 393-397.
[5] NING Shufang, WEI Wene, LI Jilin, et al. Clinical significance and diagnostic capacity of serum TK1,CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients[J]. Journal of Cancer 2018,9(3):494-501.
[6] HESS D R . A nomogram for use of non-invasive respiratory strategies in COVID-19[J]. The Lancet Digital Health, 2021,3(3):e140-e141.
[7] MANNING C, ALAM S M. Response to “A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma”[J]. Journal of Hepatology, 2020,73(5):1269-1270.
[8] 唐鹏洲, 任采月, 王月明, 等. 基于CT 影像组学列线图鉴别甲状腺良性与恶性滤泡性肿瘤的价值[J].中华放射学杂志, 2022, 56(2):136-141.
TANG Pengzhou,REN Caiyue, WANG Yueming,et al. The value of diagnostic nomogram based on CT radiomics for the preoperative differentiation between benign and malignant thyroid follicular neoplasms [J].Chinese Journal of Radiology, 2022, 56(2): 136-141.
[9] TESSLER F N, MIDDLETON W D, GRANT E G. Thyroid imaging reporting and data system (TI-RADS):A user’s guide[J].Radiology,2018,287(1):29-36.
[10] WANG Xuan, TAN Jian, ZHENG Wei, et al. A retrospective study of the clinical features in papillary thyroid microcarcinoma depending on age[J]. Nuclear Medicine Communications, 2018, 39(8):713-719.
[11] YAN Binbin, HOU Yingchen , CHEN Dong , et al. Risk factors for contralateral central lymph node metastasis in unilateral cN0 papillary thyroid carcinoma: a metaanalysis[J]. International Journal of Surgery (London,England), 2018, 59:90-98.
[12] 单立群, 崔传友, 孙景福. 桥本甲状腺炎合并甲状腺乳头状癌临床病理特征及中央区淋巴结转移的风险因素分析[J]. 中国现代普通外科进展, 2021,24(4):278-281.
SHAN Liqun, CUI Chuanyou, SUN Jingfu. Clinicopathologic features of Hashimoto’s thyroiditis complicated with papillary thyroid carcinoma and risk factors for central lymph node metastasis [J]. Chinese Journal of Current Advances in General Surgery, 2021,24(4):278-281.
[13] 刘静, 班灵英, 曹鹏. 超声在桥本甲状腺炎合并甲状腺乳头状癌诊断中的应用价值[J]. 影像研究与医学应用, 2020, 4(15):176-177.
LIU Jing, BAN Lingying, CAO Peng. The application value of ultrasound in the diagnosis of Hashimoto’s thyroiditis complicated with papillary thyroid carcinoma[J]. Journal of Imaging Research and Medical Applications, 2020, 4(15):176-177.
[14] FENG Jianhua , GAN Xiaoxiong , SHEN Fei , et al.The role of two tumor foci for predicting central lymph node metastasis in papillary thyroid carcinoma: A metaanalysis[J]. International Journal of Surgery, 2018, 52:166-170.
[15] OZDEN S, ER S, SAYLAM B, et al. A comparison of logistic regression and artificial neural networks in predicting central lymph node metastases in papillary thyroid microcarcinoma [J]. Annali Italiani di Chirurgia,2018, 89(3):193-198
[16] 刘文, 程若川, 苏艳军, 等. 甲状腺乳头状癌中央区淋巴结转移危险因素研究(附3273 例回顾性分析)[J]. 中国实用外科杂志, 2018, 38(3):316-321.
LIU Wen, CHENG Ruochuan, SU Yanjun, et al. Risk factors of central lymph node metastasis of papillary thyroid carcinoma: A single-center retrospective analysis of 3273 cases [J]. Chinese Journal of Practical Surgery, 2018, 38(3):316-321.
[17] LEE Y C , NA S Y , CHUNG H , et al. Clinicopathologic characteristics and pattern of central lymph node metastasis in papillary thyroid cancer located in the isthmus[J]. The Laryngoscope, 2016, 126(10):2419-2421.
[18] 王玲, 王健, 赵寅生, 等. 甲状腺乳头状癌患者血清促甲状腺激素水平和组织促甲状腺激素受体检测的临床应用价值[J]. 现代检验医学杂志, 2021, 36 (1):61-64.
WANG Ling,WANG Jian,ZHAO Yinsheng,et al.Clinical application value of serum thyrotropin level and tissue thyrotropin receptor detection in patients with thyroid papillary carcinoma [J]. Journal of Modern Laboratory Medicine ,2021,36(1):61-64.

相似文献/References:

[1]李桂荣,赵清侠a,宋 斌b,等.miR-221与miR-222在甲状腺乳头状癌组织中的表达及临床意义[J].现代检验医学杂志,2017,32(01):41.[doi:10.3969/j.issn.1671-7414.2017.01.012]
　LI Gui-rong,ZHAO Qing-xiaa,SONG Binb,et al.Expression of miR-221 and miR-222 in Papillary Thyroid Carcinoma Tissues and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(01):41.[doi:10.3969/j.issn.1671-7414.2017.01.012]
[2]孟凡萍,郝 坡,范 慧.甲状腺乳头状癌并发桥本氏甲状腺炎患者BRAF-V600E 基因表达及T 淋巴细胞亚群分析[J].现代检验医学杂志,2020,35(01):32.[doi:10.3969/j.issn.1671-7414.2020.01.009]
　MENG Fan-ping,HAO Po,FAN Hui.Expression of BRAF-V600E Gene and Analysis of Lymphocyte Subgroup in Thyroid Papillary Carcinoma Combined with Hashimoto's Thyroiditis[J].Journal of Modern Laboratory Medicine,2020,35(01):32.[doi:10.3969/j.issn.1671-7414.2020.01.009]
[3]王　玲,王　健,赵寅生,等.甲状腺乳头状癌患者血清促甲状腺激素水平和组织促甲状腺激素受体检测的临床应用价值[J].现代检验医学杂志,2021,36(01):61.[doi:10.3969/j.issn.1671-7414.2021.01.016]
　WANG Ling,WANG Jian,ZHAO Yin-sheng,et al.Clinical Application Value of Serum Thyrotropin Level and Tissue Thyrotropin Receptor Detection in Patients with Thyroid Papillary Carcinoma[J].Journal of Modern Laboratory Medicine,2021,36(01):61.[doi:10.3969/j.issn.1671-7414.2021.01.016]
[4]宋晓龙,宋 宇,魏 龙,等.血清TK1，TSH，TG，TGAb 检测联合TI RADS 分类在甲状腺乳头状癌早期筛查中的应用价值[J].现代检验医学杂志,2022,37(04):38.[doi:10.3969/j.issn.1671-7414.2022.04.008]
　SONG Xiao-long,SONG Yu,WEI Long,et al.Clinical Value of Serum TK1, TSH, TG and TGAb Detection Combined with TI-RADS Classification in Papillary Thyroid Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(01):38.[doi:10.3969/j.issn.1671-7414.2022.04.008]
[5]刘 星,霍占江.甲状腺乳头状癌组织中galecti-3 与miR-375 水平表达意义及相关性研究[J].现代检验医学杂志,2023,38(01):49.[doi:10.3969/j.issn.1671-7414.2023.01.010]
　LIU Xing,HUO Zhan-jiang.Expression Significance and Correlation of galectin-3 and miR-375 in Papillary Thyroid Carcinoma Tissue[J].Journal of Modern Laboratory Medicine,2023,38(01):49.[doi:10.3969/j.issn.1671-7414.2023.01.010]
[6]那将超,狄长安.甲状腺乳头状癌患者术后血清MMIF 和IL-6 表达水平与甲状旁腺功能减退持续时间的相关性研究[J].现代检验医学杂志,2023,38(01):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
　NA Jiang-chao,DI Chang-an.Correlation between Postoperative Serum MMIF and IL-6 Expression Levels and Duration of Hypoparathyroidism in Patients with Papillary Thyroid Cancer[J].Journal of Modern Laboratory Medicine,2023,38(01):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
[7]薛思军a,涂霁韬b.甲状腺乳头状癌组织中miR-137 水平表达及相关实验研究[J].现代检验医学杂志,2023,38(04):121.[doi:10.3969/j.issn.1671-7414.2023.04.022]
　XUE Sijuna,TU Jitaob.Expression of miR-137 in Papillary Thyroid Carcinoma Tissue and Its Related Experimental Study[J].Journal of Modern Laboratory Medicine,2023,38(01):121.[doi:10.3969/j.issn.1671-7414.2023.04.022]
[8]周 钧a,汪庭军b,唐 珍a.甲状腺乳头状癌患者血清EGR1/2 mRNA 水平检测在临床早期实验诊断中的价值研究[J].现代检验医学杂志,2023,38(05):93.[doi:10.3969/j.issn.1671-7414.2023.05.018]
　ZHOU Juna,WANG Tingjunb,TANG Zhena.Value of Serum EGR1/2 mRNA Detection in Early Clinical Diagnosis of Papillary Thyroid Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(01):93.[doi:10.3969/j.issn.1671-7414.2023.05.018]

备注/Memo

备注/Memo:
基金项目：陕西省科技厅一般项目（2021SF-069）。
作者简介：宋晓龙（1988-），女，硕士，主管检验技师，主要研究方向：临床检验诊断学，E-mail：zixuan_159@163.com。
通讯作者：周建平（1974-），男，硕士，副主任医师，主要从事肿瘤早期筛查和诊断工作，E-mail: zjp868@163.com。
更新日期/Last Update: 2023-01-15